Tripeptide-29
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
What it is
A tripeptide mimicking collagen's Gly-Pro-Hyp motif, marketed to boost skin collagen via fibroblast signaling. Evidence for better skin hydration and elasticity with oral use is mixed and comes mainly from collagen mixtures; wrinkle and AGE claims rest on thin, low-confidence data. Safety looks mild (rare allergy, occasional GI upset, an unestablished platelet interaction), but long-term topical data are limited. Not an approved drug; sold in cosmetics subject to applicable safety and labeling requirements.
Read Full recordStudied uses & evidence
Studied uses(6)
Stimulation of type I collagen synthesis via fibroblast signaling
MediumHuman RCT found increased dermal collagen density, mechanism supported, but not tested on this exact sequence.
Improved skin hydration and elasticity (oral supplementation)
MediumMultiple human RCTs show consistent hydration gains, though elasticity results are less consistent and industry funded.
Reduction of facial wrinkles and fine lines
LowHuman RCTs are mixed, with several showing no significant wrinkle reduction versus placebo.
Evidence limits
- Evidence Level
- Moderate
Human evidence mainly concerns collagen mixtures rather than isolated Tripeptide-29. Oral results vary by formulation and outcome, and results differ across trials. The 2021 placebo-controlled trial found reduced water loss after adjustment, without significant overall between-group improvements in hydration, elasticity, or wrinkles. A 2022 topical pilot study (PMID 35163025) in 22 women reported improvements in wrinkles, elasticity, density, and reduced AGE accumulation after 4 weeks, but it was uncontrolled and not randomized, so it cannot establish efficacy of isolated Tripeptide-29. Oral studies detect Gly-Pro-Hyp in human blood; direct skin-distribution data come from animal experiments. In vitro evidence is extensive, with well-characterized fibroblast activation via TGF-beta/Smad and MAPK/ERK pathways. A 6-month open-label trial (PMID 27725401) also reported cardiovascular marker improvements. No serious adverse events were reported across these studies. The evidence base draws on decades of collagen biology research on the Gly-Pro-Hyp motif, though large independent RCTs testing topical Tripeptide-29 as a sole active remain limited.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(4)
Risks = level of concern: High · Moderate · Low · Theoretical
Allergic or sensitivity reaction (very rare)
LowPlatelet interaction not established for isolated Tripeptide-29
TheoreticalLimited long-term topical safety data
LowGastrointestinal discomfort (oral supplementation)
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.